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Highlights of review paper 
  
 
 
Describe a major paradigm shift; from single gene causation to pathway perturbation model 
that has significantly helped our understanding the aetiology of ASD. 
We provide a comprehensive literature review of genetic screening and analysis of autism 
spectrum disorder.  
We logically progress the importance of complex network approaches for analysis of 
polygenic disorders and argue for greater consideration of the human genome as a 
preconfigured molecular system as a means to better analyze vast amounts of sequencing 
data.  
We advance the use of multilevel analysis and the importance of integrating clinical, 
behavioural and genetic data of whole families including consideration of possible broader 
autism phenotype (sub-clinical) parents.  
We showcase the specific contribution of inherited and de novo DNA variations associated 
with autism.  
We detail the enormous shift in genetic technologies and analysis skills required to handle 
vast amount of genomic metadata. 
We offer insights into further advances associated with genetic screening and data analysis 
including developing tools for autism risk prediction. 
Abstract 
The	 extreme	 genetic	 heterogeneity	 of	 autism	 spectrum	 disorder	 (ASD)	 represents	 a	
major	challenge.	Recent	advances	in	genetic	screening	and	systems	biology	approaches	
have	extended	our	knowledge	of	the	genetic	etiology	of	ASD.	In	this	review,	we	discuss	
the	paradigm	shift	from	a	single	gene	causation	model	to	pathway	perturbation	model	
as	a	guide	to	better	understand	the	pathophysiology	of	ASD.	We	discuss	recent	genetic	
findings	 obtained	 through	 next‐generation	 sequencing	 (NGS)	 and	 examine	 various	
integrative	 analyses	 using	 systems	 biology	 and	 complex	 networks	 approaches	 that	
identify	convergent	patterns	of	genetic	elements	associated	with	ASD.		
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1. Introduction 
Autism	spectrum	disorder	(ASD)	is	a	highly	heritable	neurodevelopmental	disorder	that	
affects	up	to	1‐2%	of	the	population	(Autism	et	al.,	2012;	Devlin	and	Scherer,	2012).	It	is	
characterized	 by	 impaired	 social	 interactions,	 communication	 deficits	 and	 repetitive	
behavior.	Moreover,	ASD	is	often	comorbid	with	other	phenotypic	and	clinical	features,	
such	 as	 motor	 impairments,	 sleep	 disturbance,	 and	 sensory	 abnormalities.	 Not	
surprisingly,	 ASD	 is	 characterized	 by	 both	 genetic	 and	 phenotypic	 heterogeneity,	 and	
there	is	a	high	level	of	variation	between	individuals	diagnosed	with	autism.		
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Over	the	last	five	years,	technological	advances	have	facilitated	identification	of	causal	
DNA	 variants	 associated	 with	 ASD.	 Advances	 in	 next‐generation	 sequencing	 (NGS),	
whole‐exome	 sequencing	 (WES),	 and	whole‐genome	 sequencing	 (WGS)	 have	 enabled	
the	identification	of	large	numbers	of	rare	single	nucleotide	variants	(SNVs),	 including	
small	insertion/deletion	mutations	(indels)	that	are	associated	with	ASD.	Furthermore,	
family‐based	sequencing	(trio	and	sibling	families)	has	helped	to	disentangle	the	causal	
relationship	of	de	novo	and	inherited	variants	(Ku	et	al.,	2013;	Stein	et	al.,	2013),	such	
that,	 we	 now	 understand	 there	 are	 hundreds	 of	 genetic	 variations	 that	 affect	 a	wide	
range	 of	 molecular	 functions	 associated	 with	 ASD	 (Betancur,	 2011b;	 Buxbaum	 et	 al.,	
2012;	Stein	et	 al.,	 2013).	More	 importantly,	 these	genes	are	not	 randomly	distributed	
but	converge	in	functionally	relevant	biological	processes	such	as	synapse	development	
and	transcriptional	regulation	in	the	brain.	Thus,	the	challenge	that	arises	is	to	find	and	
precisely	identify	potentially	hundreds	of	heterogeneous	DNA	variations	that	converge	
in	functional	pathways	associated	with	ASD.	This	requires	refocusing	molecular	related	
morbidity	 paradigms	 from	 single	 or	 a	 few	 unrelated	 coding	 genes	 to	 functional	
networks	 of	 genes	 that	 contribute	 to	 key	 neurodevelopmental	 and	 neurological	
processes.	
Systems	 biology	 and	 complex	 networks	 approaches	 are	 now	 being	 used	 to	 build	 the	
relationships	between	biological	elements	among	heterogeneous	components.	This	has	
been	important	to	focus	on	a	level	of	resolution	that	allows	us	to	‘see	the	forest	for	the	
trees’.	 We	 are	 mindful	 that	 ‘nothing	 in	 biology	 makes	 sense	 except	 in	 the	 light	 of	
evolution’	(Dobzhansky,	1973),	and	that	evolutionary	constraint	underpins	the	fidelity	
of	genes	and	molecules	that	function	in	biological	process.	Importantly,	this	has	led	to	a	
shift	 from	 an	 exclusive	 reliance	 on	 statistical	 genetics	 to	 more	 appropriately	
	 5
understanding	 the	 evolutionary	 preconfigured	 nature	 of	 a	 biological	 system	 and	
complex	molecular	networks	that	underpin	human	development.	The	application	of	the	
systems	 paradigm	 in	 mental	 health	 research	 allows	 us	 to	 examine	 the	 relevance	 of	
combinations	 of	 genetic	 elements	 that	 putatively	 impact	 on	 biological	 functions	
associated	with	ASD.		
Much	of	 the	 scientific	momentum	regarding	 systems	approaches	 comes	 from	 traction	
arising	 from	many	different	omics	data	(Mitra	et	al.,	2013),	 increasing	our	capacity	 to	
generate	 new	models,	 for	 hypothesis‐driven	 analyses	 of	 genetic	 data	 (Barabasi	 et	 al.,	
2011).	 This	 has	 led	 to	 the	 development	 of	 integrative	 approaches	 involving	multiple	
data	sources,	model	construction,	and	complex	network	analyses.	Here,	we	provide	an	
overview	 of	 recent	 genetic	 studies	 for	 large	 ASD	 cohorts.	 For	 this,	 we	 performed	 a	
PubMed	 (http://www.ncbi.nlm.nih.gov/pubmed)	 literature	 search	 to	 identify	 studies	
published	 in	 peer‐reviewed	 journals	 with	 titles	 or	 abstracts	 matching	 the	 following	
search	criteria:	“autism	AND	genome	sequencing”	OR	“autism	AND	exome	sequencing”,	
and	then	rigorously	and	manually	inspected	43	and	122	articles	respectively,	to	select	
studies	 that	 primarily	 generated	 genomic	 sequencing	 data	 of	 ASD.	 We	 also	 sought	
research	 articles	 that	 utilized	 systems	 approaches	 for	 ASD,	 which	 have	 titles	 or	
abstracts	 matching	 the	 following	 search	 criteria:	 "autism	 AND	 systems	 biology"	 OR	
"autism	AND	complex	network	 analysis",	 that	 uncovered	109	 results.	We	are	mindful	
the	 systems	 paradigm	 when	 applied	 to	 genetic	 screening	 data	 involves	 interpreting	
functionalities	 of	 genes	 and	biological	 pathways	 that	 have	been	preconfigure	 through	
millions	 of	 years.	 In	 this	 regard	 both	 rare	 variations	 detected	 from	 whole	 genome	
sequencing	 and	 common	 variations	 identified	 by	 population	 based	 Genome	 Wide	
Association	 Studies	 (GWAS	 )	 approaches	 can	 be	 used	 to	 construct	models	 describing	
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aberrant	 functionalities	 associated	with	ASD.	This	 review	 summarizes	 the	move	 from	
single	 gene	 to	 biological	 pathway	 causation	 models	 of	 autism	 and	 the	 role	 ‘systems	
biology’	is	playing	in	accommodating	this	paradigm	shift.	 
2. Recent genetic findings associated with ASD 
2.1. De novo variants  
The	identification	of	de	novo	variants	(DNVs)	is	a	major	genetic	finding	associated	with	
ASD.	DNVs	are	DNA	variants	that	occur	spontaneously	in	the	parental	germline	during	
meiosis	(Conrad	et	al.,	2011).	Similar	to	inherited	variants,	DNVs	comprise	a	wide	range	
of	 genomic	 alterations,	 including	 chromosomal	 variations,	 copy‐number	 variations	
(CNVs;	 >1kb),	 small	 insertions/deletions	 (indels;	 2‐1,000bp)	 and	 single	 nucleotide	
polymorphisms	(SNPs;	1bp).	On	average,	approximately	40	DNVs	are	thought	to	arise	in	
an	 individual's	genome	(Conrad	et	al.,	2011).	Most	DNVs	appear	to	be	correlated	with	
paternal	age	(Flatscher‐Bader	et	al.,	2011;	Hultman	et	al.,	2011;	Malaspina	et	al.,	2001;	
McGrath	 et	 al.,	 2014),	 aging	 progenitor	 germ‐line	 cells	 involved	 in	 spermatogenesis	
introduce	 errors	 during	 replication,	 thereby	 increasing	 the	 rate	 of	DNVs	 (Kong	 et	 al.,	
2012;	O'Roak	et	al.,	2011).	In	sporadic	cases	of	ASD	(i.e.,	ASD	probands	with	unaffected	
parents),	DNVs	have	been	reported	to	have	a	large	genetic	effect,	as	they	have	not	been	
subject	 to	 natural	 selection	 processes	 in	 previous	 generations	 (Crow,	 2000;	 Eyre‐
Walker	and	Keightley,	2007).		
A	number	of	large‐scale	genetic	screening	studies	have	used	SNP	genotyping	arrays	to	
focus	on	copy	number	variations	(CNVs).	These	studies	successfully	 identified	de	novo	
events	associated	with	ASD	(Levy	et	al.,	2011;	Marshall	et	al.,	2008;	Pinto	et	al.,	2010;	
Sanders	 et	 al.,	 2011;	 Sebat	 et	 al.,	 2007;	 Szatmari	 et	 al.,	 2007).	 The	 results	 highlight	
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several	 loci	were	characterized	by	recurrent	de	novo	CNVs,	 including	1q21.1,	7q11.23,	
15q11‐13,	 16p11.2,	 17q12,	 and	 22q11.2.	 These	 CNVs	 are	 larger	 DNA	 duplications	 or	
deletions	 that	 encompass	 multiple	 genes	 or	 regulatory	 regions	 and	 are	 expected	 to	
impart	 a	 substantial	 risk	 for	 certain	 phenotypes.	 Many	 of	 these	 de	novo	 CNVs	 were	
shown	to	affect	important	synaptic	genes,	such	as	NRXN1	(Szatmari	et	al.,	2007),	NLGN3	
(Sanders	et	al.,	2011),	SHANK3	(Marshall	et	al.,	2008),	SHANK2	(Berkel	et	al.,	2010),	and	
SYNGAP1	 (Pinto	 et	 al.,	 2010),	 suggesting	 synaptic	 dysfunction	 or	 perturbation	 of	
synapse	 development	 may	 underlie	 the	 pathophysiology	 of	 ASD.	 Indeed,	 subsequent	
studies	 using	 animal	 models	 and	 transcriptomics	 data	 have	 elucidated	 functional	
changes	associated	with	these	CNVs	(Durand	et	al.,	2012;	Golzio	et	al.,	2012;	Luo	et	al.,	
2012;	Won	et	al.,	2012).	De	novo	CNVs	have	an	increased	frequency	in	individuals	with	
ASD	compared	with	unaffected	controls,	 in	contrast	 to	 inherited	CNVs,	which	occur	at	
similar	rates	between	cases	and	controls.	Although	there	 is	an	enriched	occurrence	of	
de	novo	CNVs	in	ASD	cases	(accounting	for	only	5‐10%	of	total	ASD	cases)	and	low	co‐
occurrence	in	unaffected	controls	(~1%)	(Carter	and	Scherer,	2013;	Geschwind,	2011)	
many	CNVs	are	not	causally	related	or	fully	penetrant	in	ASD	(Bucan	et	al.,	2009).		
Despite	some	success	showing	CNVs	being	causatively	associated,	 the	SNP	genotyping	
array	 approach	 has	major	 limitations.	 This	 is	 because	 of	 the	 large	 genomic	 intervals	
between	SNP	markers	which	preclude	reliably	investigating	SNPs	or	indels	that	occur	in	
the	 intervening	 space.	 In	 contrast	 recent	 genome	 sequencing,	 allows	 point	mutations	
and	 indels	 (DNA	 variations)	 to	 be	 examined	 on	 the	 basis	 of	 hundreds	 of	 millions	 of	
sequence	reads.	For	example,	high‐fidelity	whole‐exome	sequencing	(WES)	 focuses	on	
genetic	 information	of	protein‐coding	 transcripts	 and	 their	 nearby	 regulatory	 regions	
(Bamshad	et	al.,	2011).	Alternatively,	whole‐genome	sequencing	(WGS)	provides	a	more	
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comprehensive	 readout	across	 the	entire	genome	but	 it	 is	 computationally	difficult	 to	
analyze	and	currently	still	significantly	more	expensive	than	WES.		
Since	the	introduction	of	WES	and	WGS,	increasing	evidence	has	linked	DNVs	with	ASD.	
Recent	 family‐based	 studies	 identified	 thousands	 of	 DNVs	 in	 a	 large	 number	 of	 ASD	
probands	and	their	siblings	(Table	1).	Loss‐of‐function	variants	(LoF	variants)	–	those	
annotated	as	nonsense	variants,	frameshifts	or	splice	site	changes	–	occur	at	twice	the	
frequency	in	probands	(roughly	0.21	per	child)	than	in	unaffected	siblings	(roughly	0.12	
per	child)	(Iossifov	et	al.,	2014).	For	this	reason,	de	novo	LoF	variants	are	considered	to	
provide	one	of	the	major	genetic	contributions	to	sporadic	cases	(Hoischen	et	al.,	2014;	
Ronemus	et	al.,	2014).	Importantly,	two	recent	large	exome	studies,	involving	3,871	and	
2,508	cases	revealed	multiple	de	novo	LoF	variants	occur	in	coding	genes	–	ADNP,	ANK2,	
ARID1B,	 CHD8,	 DYRK1A,	 GRIN2B,	 KATNAL2,	 POGZ,	 SCN2A,	 and	 TBR1	 (Iossifov	 et	 al.,	
2014;	Poultney	et	al.,	2014).		
De	novo	missense	 variants	 are	 the	most	 abundant	 type	 of	 DNV	 (approximately	 60%)	
identified	 in	 WES	 and	 WGS	 studies.	 Although	 they	 are	 thought	 to	 account	 for	
approximately	 10%	 of	 ASD	 cases	 (Ronemus	 et	 al.,	 2014),	 it	 is	 difficult	 to	 determine	
whether	de	novo	missense	 variants	 show	 greater	 frequency	 in	 ASD	 probands	 than	 in	
unaffected	siblings.	Recent	studies	reported	the	rate	of	de	novo	missense	variants	was	
increased	 in	 probands	 versus	 siblings	 (O'Roak	 et	 al.,	 2012;	 Sanders	 et	 al.,	 2012),	 but	
another	study	did	not	detect	 this	difference	(Iossifov	et	al.,	2012).	Nevertheless,	 there	
are	 a	 few	 factors	 that	 should	 be	 taken	 into	 consideration	 when	 estimating	 their	
contributions.	Firstly,	most	de	novo	missense	variants	result	 in	deleterious	amino	acid	
substitutions	 (Table	1),	 and	 their	 individual	 effects	 must	 be	 considered	 in	 terms	 of	
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structural	 modification	 and	 functional	 consequence	 (binding,	 dimerization,	 catalysis,	
post‐translational	 modification)	 to	 the	 protein	 or	 isoform	 protein	 .	 Secondly,	 a	 large	
number	of	de	novo	missense	variants	found	in	the	same	gene	are	required	to	establish	a	
significant	 association	 with	 ASD	 (Sanders	 et	 al.,	 2012).	 Thirdly,	 de	 novo	 missense	
variants	 have	 been	 found	 to	 be	 overrepresented	 during	 early	 neurodevelopment	 and	
prenatal	development	(Parikshak	et	al.,	2013).		
Interestingly,	there	are	numerous	recurring	variants	observed	in	ASD	probands.	These	
include	various	types	of	DNVs	that	occur	in	coding	regions	of	SCN2A	(Sodium	Channel,	
Voltage‐Gated,	Type	 II,	Alpha	 subunit)	were	 found	 in	 four	different	 studies	 (An	 et	 al.,	
2014;	Iossifov	et	al.,	2012;	Jiang	et	al.,	2013;	Sanders	et	al.,	2012).	We	also	know	many	
of	the	recurrent	DNVs	have	been	associated	with	other	neurodevelopmental	disorders,	
such	 as	 intellectual	 disabilities,	 epileptic	 encephalopathy’s	 and	 schizophrenia,	
suggesting	there	is	high	molecular	comorbidity	between	these	disorders	(Iossifov	et	al.,	
2014;	Li	et	al.,	2015;	Poultney	et	al.,	2014).	Cristino	et	al.	recently	demonstrated	there	is	
significant	 molecular	 overlap	 between	 neurodevelopmental	 and	 neuropsychiatric	
disorders	 (Cristino	 et	 al.,	 2014a).	 Apart	 from	 recurrent	 genes	 containing	 DNVs,	 it	 is	
noteworthy	 that	 there	 is	 an	 increased	 frequency	 of	 DNVs	 occurring	 in	 several	 gene	
families.	 These	 include	 voltage‐gated	 calcium	 channel	 (CACNA),	 catenin	 (CTNN),	 and	
chromodomain	 helicase	 DNA	 binding	 protein	 (CHD)	 gene	 families	 that	 appear	 to	
contribute	 to	 specific	 ASD	 phenotypes	 (Bernier	 et	 al.,	 2014;	 Pinggera	 et	 al.,	 2015;	
Turner	 et	 al.,	 2015).	 This	 increased	 frequency	 of	 DNVs	 in	 specific	 gene	 families	
highlights	 related	 genes	 with	 overlapping	 function	 contribute	 to	 biological	 pathways	
and	 processes	 associated	 with	 synapse	 development	 and	 function,	 neuronal	
development,	and	chromatin	modulation	(Figure	1).	
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2.2. Rare inherited variants  
In	 contrast	 to	 DNVs,	 inherited	 variants	 account	 for	 the	 greatest	 number	 of	 genetic	
alterations	 in	human	genomes	and	 can	be	 classified	as	either	 common	or	 rare	on	 the	
basis	 of	 their	 frequency	 in	 the	population.	Although	both	 common	and	 rare	 inherited	
variants	may	contribute	to	the	development	of	ASD,	rare	variants	are	expected	to	have	a	
larger	effect	than	individual	common	variants	(State	and	Levitt,	2011;	Stein	et	al.,	2013).	
Importantly,	 recent	WES	studies	have	successfully	 identified	a	range	of	 rare	 inherited	
variants	associated	with	ASD	(An	et	al.,	2014;	Lim	et	al.,	2013;	Toma	et	al.,	2014;	Yu	et	
al.,	2013).		
Rare	 complete	 knockouts	 (homozygous	 and	 compound	 variants)	 have	 typically	 been	
associated	with	Mendelian	disorders	because	they	more	obviously	result	in	deleterious	
phenotypes.	 Lim	 et	al.	 recently	 reported	 rare	 complete	 knockouts	 in	ASD	 cases	 using	
WES	analysis	of	933	ASD	cases	and	869	controls	to	examine	(Lim	et	al.,	2013).		Among	
the	933	ASD	cases	and	869	controls	examined	there	were	91	rare	complete	knockouts	
were	found.	These	occur	at	twice	the	frequency	in	cases	(n=62)	than	in	controls	(n=29),	
and	the	authors	concluded	this	incidence	accounts	for	~3%	of	ASD	cases.	This	disparity	
was	 not	 observed	 for	 rare	 heterozygous	 variants.	 Of	 particular	 interest	was	 the	 high	
occurrence	 of	 rare	 complete	 knockouts	 associated	 with	 the	 X‐chromosome	 in	 cases	
compared	with	the	controls.	The	predominant	of	hemizygous	variants	found	in	males	or	
homozygous	variants	in	females	are	estimated	to	account	for	another	2%	of	ASD	cases.	
In	another	study	by	Yu	et	al.,	heterozygous	mapping	and	 linkage	analysis	was	used	to	
examine	consanguinity	 in	 familial	ASD	cases	 (Yu	et	al.,	2013).	The	authors	 found	rare	
LoF	 and	 missense	 variants	 associated	 with	 AMT,	 PEX7	 and	 SYNE1	 genes.	 They	 also	
examined	 protein‐altering	 variants	 (missense,	 nonsense,	 splice	 site,	 and	 frameshift	
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mutations)	 present	 at	 low	 frequencies	 in	 the	 population.	 The	 analysis	 of	 70	 genes	
previously	 associated	 with	 ASD	 identified	 an	 excessive	 number	 of	 monogenic,	
autosomal	 recessive	 or	 X‐linked	 variants	 (Betancur,	 2011a).	 They	 found	 five	 families	
affected	 by	 rare	 homozygous,	 compound	 heterozygous,	 or	 hemizygous	 variants.	 For	
example,	 a	 nonsense	 hemizygous	 variant	 occurring	 in	NLGN4X	 was	 identified	 in	 one	
family;	this	variant	was	inherited	from	an	unaffected	mother	in	an	affected	male	child.	
Another	family	showed	the	same	inheritance	pattern	for	a	nonsense	hemizygous	variant	
of	MECP2.	Although	 some	 rare	homozygous	variants	 can	explain	 the	 etiology	of	 some	
families	 with	 clinical	 phenotypes	 associated	 with	 certain	 syndromes	 (e.g.,	
phenylketonuria,	 dysmorphic	 features	 or	 microcephaly)	 others	 occur	 in	 unaffected	
siblings	or	cases	that	do	not	show	clear	phenotypes,	suggesting	hypomorphic	variants	
or	other	genes	might	be	involved.	
Two	WES	studies	have	analyzed	the	role	of	rare	heterozygous	variants	in	ASD.	In	some	
multiplex	ASD	families	rare	heterozygous	truncating	variants	–	nonsense	and	frameshift	
variants	 –	 are	 more	 frequently	 inherited	 from	 parents	 than	 non‐truncating	 variants.	
More	 importantly,	 there	 is	 an	 inverse	 correlation	 between	 the	 number	 of	 rare	
heterozygous	truncating	variants	and	non‐verbal	intelligence	quotient	(NVIQ)	has	been	
observed	(Toma	et	al.,	2014),	confirming	previous	observation	concerning	an	increased	
number	of	DNVs	and	decreased	NVIQ	(O'Roak	et	al.,	2012).	However,	this	study	did	not	
ascertain	 the	 contribution	 of	 rare	 heterozygous	 missense	 variants.	 More	 recent	
evidence	showed	that	rare	heterozygous	missense	variants	appear	to	contribute	to	the	
etiology	of	ASD.	Recently,	An	et	al.	(2014)	investigated	significance	of	rare	heterozygous	
variants	identified	by	stringent	filtering	of	sequence	data.	Rare	variants	were	defined	as	
those	that	a)	showed	a	minor	allele	 frequency	(MAF)	of	<1%	or	were	unknown	in	the	
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1,000	 Genomes	 Project	 and	 NHLBI	 Exomes	 database	 and	 b)	 were	 predicted	 to	 be	
deleterious	 by	 SIFT	 and	 PolyPhen2.	 This	 analysis	 identified	 ~125	 rare	 variants	 per	
individual.	 These	 variants	 were	 significantly	 enriched	 in	 genes	 that	 were	 previously	
associated	 with	 ASD	 and	 correlated	 with	 the	 level	 of	 rarity	 (i.e.	 MAF	 or	 prediction	
scores).	 Moreover,	 inherited	 variants	 from	 parents	 with	 broader	 autism	 phenotype	
(BAP),	a	weak	phenotype	of	ASD	(Taylor	et	al.,	2013),	were	enriched	in	ASD‐associated	
genes	compared	with	inherited	variants	from	parents	without	BAP.	Taken	together,	this	
evidence	 indicates	 that	 rare	heterozygous	variants	make	a	 cumulative	contribution	 to	
ASD.		
	
2.3. Common variants associated with ASD 
Common	 DNA	 variants	 associated	 with	 ASD	 are	 estimated	 to	 occur	 in	 >1%	 of	 the	
population.	 Unlike	 rare	 variants,	 individual	 common	 variants	 are	 thought	 to	 have	 a	
small	 effect	 size	 or	 possibly	 benign	 even	 effect	 on	disease	 (Geschwind	&	 State,	 2015;	
Gratten,	Wray,	Keller,	&	Visscher,	2014).	Most	common	variant	estimations	have	been	
calculated	 from	 imputed	 SNP	 markers	 found	 in	 Genome	 Wide	 Association	 Studies.	
These	variants	are	thought	to	exist	in	large	intervening	genomic	regions	and	predicted	
to	be	co‐inherited	due	 to	uneven	patterns	of	 recombination	 in	a	given	genetic	cohort.	
Despite	 small	 effect	 size,	 it	 is	 generally	 understood	 that	 common	 variants	 may	
contribute	 to	 polygenic	 disorders	 by	 epistatic	 interaction	 whereby	 combinations	 of	
common	variants	increase	the	threshold	of	genetic	liability.	
In	ASD,	common	variants	are	thought	to	account	for	40%	of	the	genetic	risk	(Stein	et	al.,	
2014).	 There	 are	 some	 common	 variants	 identified	 in	 several	 large	 genome	 wide	
association	studies	‐	rs4307059	in	the	5p14.1	region	(Wang	et	al.,	2009),	rs10513025,	
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rs10513026,	rs16883317	in	the	5p15.2	(Weiss	et	al.,	2009),	rs4141463	in	the	20p12.1	
region	(Anney	et	al.,	2010),	and	rs936938,	rs6537835,	rs1877455	in	the	1p13.2	region	
(Xia	et	al.,	2014).	 	These	common	variants	encompass	 the	regions	near	CDH9,	CDH10,	
CSDE1,	MACROD2,	NRAS,	 SEMA5A,	TAS2R1,	 and	TRIM33	 gene.	 Despite	 these	 genome‐
wide	significant	hits,	none	of	these	have	been	consistently	replicated	across	studies	due	
to	arguably	underpowered	sample	size.	Given	the	successful	report	of	common	loci	 in	
schizophrenia	 (Schizophrenia	 Working	 Group	 of	 the	 Psychiatric	 Genomics,	 2014),	
another	genetically	heterogeneous	neuropsychiatric	disorder,	much	larger	family‐based	
cohorts	are	arguably	essential	for	progressing	this	approach.	
To	overcome	phenotypic	heterogeneity	in	ASD,	a	number	of	other	studies	have	focused	
on	a	range	of	associated	phenotypes	(sub‐phenotype)	of	ASD	and	reported	susceptible	
genetic	 loci	 associated	 with	 each	 sub‐phenotype.	 For	 instance,	 delayed	 language	
acquisition	has	been	found	to	be	associated	with	the	3p12.3	(St	Pourcain	et	al.,	2014).	
This	region	contains	the	ROBO2	gene	 that	encodes	a	conserved	axon‐binding	receptor	
reported	 to	 have	 decreased	 gene	 expression	 in	 the	 anterior	 cingulate	 cortex	 in	 ASD	
cases	 (Suda	 et	 al.,	 2011).	 Another	 common	 genetic	 association	 was	 observed	 in	 the	
7q35	 region	 (Alarcon	 et	 al.,	 2002),	 encompassing	CNTNAP2	 gene.	This	might	 indicate	
there	 is	 a	 locus‐specific	 sub‐phenotype	 that	 maybe	 broadly	 represented	 in	 the	
population	 (Jonsson	 et	 al.,	 2014).	 Apart	 from	 these	 examples,	 several	 other	 studies	
examined	 the	 common	 genetic	 variations	 associated	 with	 learning	 and	 cognitive	
capability.	In	a	recent	study	of	high‐functioning	ASD	cases	researchers	found	a	variant	
(rs17225178)	 in	 the	 ARNT2	 gene	 (Di	 Napoli,	 Warrier,	 Baron‐Cohen,	 &	 Chakrabarti,	
2015),	which	encodes	an	important	transcription	factor.	Interestingly,	ARNT2	is	known	
to	regulate	cellular	responses	to	hypoxia	via	dimerization	with	HIF1A	in	central	nervous	
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system	 (Michaud,	 DeRossi,	 May,	 Holdener,	 &	 Fan,	 2000).	 	 Common	 variants	 from	
individuals	with	learning	difficulties	e.g.	rs789859	in	the	3q29	region	(Baron‐Cohen	et	
al.,	2014)	have	also	been	associated	with	ASD	and	this	region	has	been	shown	to	harbor	
a	 de	 novo	 deletion	 in	 neuropsychiatric	 cases	 with	 learning	 difficulties	 (Sagar	 et	 al.,	
2013).		
	
	
3. Convergence of DNA variations underlie ASD 
The	 extreme	 genetic	 heterogeneity	 found	 in	 ASD	 represents	 a	 huge	 challenge	 in	
attempting	 to	 understand	 the	 etiology	 and	 development	 of	 autism	 (Betancur,	 2011a;	
Geschwind,	2011).	 In	 the	 absence	of	 any	 specific	 gene	 responsible	 for	 the	majority	of	
ASD	 cases,	 the	 most	 common	 genes	 only	 account	 for	 approximately	 2%	 of	 ASD	
(Abrahams	 and	 Geschwind,	 2008).	 Furthermore,	 it	 has	 been	 shown	 that	 candidate	
genes	 cover	 a	wide	 range	 of	 functions,	 including	 cell‐cell	 adhesion,	 synaptic	 activities	
and	 neurotransmission,	 transcriptional	 regulation,	 and	 activity‐dependent	 protein	
translation,	 and	 possibly	 contribute	 to	 a	 number	 of	 common	 clinical	 features	 that	
accompany	ASD	(Abrahams	and	Geschwind,	2008),	which	are	generally	devalued	in	the	
diagnostic	 processes	 and	 in	 the	 discovery	 of	 candidate	 genes	 (Jeste	 and	 Geschwind,	
2014;	 Stessman	 et	 al.,	 2014).	 For	 this	 reason,	 ASD	 should	 be	 considered	 as	 a	
combination	 of	 phenotypes,	 not	 as	 a	 disorder	 caused	 by	 any	 individual	 gene	
(Geschwind,	2011;	Mitchell,	2012).	It	is	therefore	essential	to	examine	the	contribution	
of	the	many	candidate	ASD	genes	with	respect	to	functions	that	contribute	to	diagnostic	
behaviors	in	order	to	elucidate	the	numerous	subtypes	of	ASD.		
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This	 situation	 has	 led	 to	 the	 emergence	 of	 new	 approaches	 for	 detecting	 molecular	
convergence	 associated	 with	 ASD.	 There	 are	 now	 a	 number	 of	 studies	 that	 have	
attempted	to	resolve	whether	putative	candidate	genes	converge	in	specific	molecular	
or	 biological	 processes.	 These	 studies	 are	 based	 on	 the	 premise	 that	 convergent	
pathway(s)	 and	 the	 co‐expression	 or	 functional	 proximity	 of	 candidate	 genes	 display	
distinctive	patterns	of	interaction	and	provide	a	segue	for	systems	biology	analyses.		
3.1. Interconnection of genes  
Many	 studies	have	 investigated	 the	 convergence	of	ASD‐associated	CNVs	 in	biological	
pathways.	Gilman	et	al.	developed	the	Network‐Based	Analysis	of	Genetic	associations	
(NETBAG)	technique	for	this	purpose	(Gilman	et	al.,	2011).	This	method	was	designed	
to	 identify	 combinations	 of	 genes	 contributing	 to	 any	 one	 disorder,	 based	 on	 the	
hypothesis	 that	 these	 genes	 contribute	 to	 phenotypes	 typical	 of	 a	 disorder.	 NETBAG	
used	high‐confidence	datasets	of	ASD‐associated	CNVs	(Levy	et	al.,	2011)	and	showed	
these	 were	 enriched	 in	 pathways	 related	 to	 synaptogenesis,	 cell‐cell	 adhesion,	 axon	
guidance,	neuronal	motility,	GTPase	signaling	and	the	actin	cytoskeleton.	This	method	
was	later	applied	to	examine	a	large	sample	set,	and	helped	to	identify	a	network	of	113	
de	 novo	 CNVs,	 enriched	 in	 functions	 associated	 with	 chromatin	 and	 transcription	
regulation,	MAPK	signaling,	and	synaptic	development	(Pinto	et	al.,	2014).	Interestingly,	
putative	functional	perturbations	associated	with	CNVs	are	more	pronounce	in	females	
than	in	males,	consistent	with	the	idea	of	highly	penetrance	CNVs	occurring	in	females	
(Pinto	et	al.,	2014).	By	considering	duplication	and	deletion	variations,	Noh	et	al.	have	
further	elucidated	the	phenotypic	consequences	of	CNVs	(Noh	et	al.,	2013).		
Importantly,	pathways	relevant	 to	synaptic	 functions	have	repeatedly	been	associated	
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with	ASD	pathology	 (Betancur	et	al.,	2009;	Toro	et	al.,	2010).	 Sakai	et	al.	 (Sakai	et	al.,	
2011)	 highlight	 how	 CNVs	 converge	 in	 neuronal	 post‐synaptic	 processes	 in	 ASD.	
Specifically,	 they	 used	 a	 yeast	 two‐hybrid	 system	 to	 examine	 protein‐protein	
interactions.	They	 found	genes	 from	ASD	 cases	had	 greater	 connectivity	 compared	 to	
non‐ASD	 individuals.	Many	 key	 genes	 (or	 hub	 genes)	 that	 interact	 with	 a	 number	 of	
other	 genes	 (protein‐protein	 interactions)	 are	more	 frequently	 associated	with	 CNVs	
found	in	ASD	cases.	For	example,	SHANK3	 is	connected	with	a	number	of	postsynaptic	
genes	 (e.g.,	PSD95,	TSC1,	ACTN1,	 and	HOMER3).	 In	vivo	 evidence	 (Becker	 et	 al.,	 2014;	
Tsai	et	al.,	2012)	confirms	the	post‐synaptic	complex	is	an	important	contributor	to	ASD	
pathophysiology	(Berg	and	Geschwind,	2012).	
This	 integrative	 approach	 provides	 a	 basis	 for	 constructing	 more	 comprehensive	
models	 for	 conceptualizing	 the	 molecular	 relationship	 between	 ASD	 and	 other	
neurodevelopmental	 and	neuropsychiatric	disorders.	Cristino	et	al.	 (2014a)	 examined	
the	 functional	 patterns	 of	 candidate	 genes	 associated	 with	 ASD,	 X‐linked	 intellectual	
disability	 (XLID),	 attention	 deficit	 hyperactivity	 disorder	 (ADHD)	 and	 schizophrenia	
(SZ).	In	this	study,	candidate	disorder	genes	and	their	first‐degree	interacting	proteins	
were	used	 to	create	a	comprehensive	protein‐protein	 interaction	network,	which	was	
collectively	referred	 to	as	 the	AXAS‐PPI	network.	 Interestingly,	 the	AXAS‐PPI	network	
was	shown	to	have	significantly	more	connections	with	increased	structural	properties	
(e.g.,	 in	 terms	 of	 the	 average	 degree,	 density	 and	 clustering	 coefficient)	 compared	 to	
networks	 created	 from	 an	 equivalent	 number	 of	 randomly	 selected	 genes	 in	 the	
genome.	 This	 confirmed	 the	 AXAS	 network	 reflects	 meaningful	 biological	 signal,	
confirming	neighboring	candidate	genes	function	in	the	related	biological	processes	and	
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pathways.	Closer	examination	revealed	this	AXAS	network	is	divided	into	30	functional	
modules,	with	unique	patterns	of	gene	distributions	across	the	four	disorders	and	this	
can	be	used	to	analyze	the	relationship	of	DNA	variations	with	different	disorders.	For	
instance,	the	module	for	synapse	development	and	signal	transduction	was	shown	to	be	
the	 largest	with	 disorder	 genes	 being	 equally	 distributed.	 	 Synapse	 development	 and	
signal	 transduction	may	 therefore	 be	 key	 biological	 processes	 common	 to	ASD,	 XLID,	
ADHD	 and	 SZ.	 This	 is	 consistent	 with	 the	 number	 of	 studies	 that	 highlight	 the	
importance	of	synaptic	genes	(DLG3,	DLG4,	GRIN1,	GRIN2B,	PRKCB,	STX1B,	STXBP1,	and	
SYNGAP1)	 in	ASD,	epilepsy,	 intellectual	disabilities	and	schizophrenia	(Hormozdiari	et	
al.,	2015).		
Complex	network	models	 are	now	proving	 to	be	powerful	 tools	 for	 analyzing	 genetic	
screening	 data	 and	 abstracting	 the	 molecular	 basis	 of	 neurodevelopmental	 and	
neuropsychiatric	 disorders.	 An	 et	al.	 (2014)	 utilized	 the	 AXAS	model	 to	 analyze	WES	
sequencing	 data	 and	 identify	 patterns	 of	 candidate	 genes	 that	 are	 putatively	
overrepresented	in	functional	processes	and	pathways	associated	with	ASD.	They	found	
approximately	100	rare	variants	per	individual	case	were	distributed	across	a	number	
of	 different	 biological	 pathways	 and	 processes.	 For	 instance,	 rare	 variants	 from	 four	
ASD	 probands	 were	 clustered	 in	 the	 L1CAM	 pathway	 including	 combinations	 of	 rare	
inherited	variants	and	DNVs.	This	 result	 showed	 there	was	molecular	 convergence	of	
predominantly	 heterozygous	 variants	 in	 families	 with	 ASD.	 Their	 data	 suggests	
combinations	 of	weak	 heterozygous	 alleles	 converge	 in	 common	 biological	 processes	
and	 likely	 contribute	 to	 increase	 threshold	of	 liability	associated	with	ASD.	Again,	 the	
clustering	phenomena	were	observed	in	pathways	related	to	synaptic	function	(e.g.	the	
neurexin	 trans‐synaptic	 complex).	 Indeed,	 by	 examining	 the	 distribution	 of	 rare	
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variants	 among	 interacting	 proteins	 involved	 in	 synapse	 development	 and	 function,	
they	confirm	previously	reported	pattern	of	pervasive	rare	variants	(Kenny	et	al.,	2014).		
The	 interconnection	 of	 ASD	 genes	 has	 been	 further	 investigated	 by	 considering	 the	
expression	of	alternative	spliced	genes.	Corominas	et	al.	(2014)	built	a	PPI	network,	the	
Autism	 Splice‐form	 Interaction	Network	 (ASIN),	 based	 on	 alternatively	 spliced	 brain‐
expressed	isoforms	and	genetic	associations	(Corominas	et	al.,	2014).	The	background	
interactions	of	the	ASIN	consisted	of	experimentally	validated	isoforms	generated	from	
high‐throughput	 transcriptomics	 sequencing,	 but	 the	 data	 suffered	 from	 a	 lack	 of	
spatiotemporal	evidence	due	 to	 the	use	of	only	 two	adult	brain	samples	(one	 from	an	
18‐year‐old	male	and	another	from	a	66‐year‐old	female).	Interestingly,	the	interacting	
partners	 of	 the	 ASIN	 were	 enriched	 for	 rare	 de	novo	 CNVs.	 This	 is	 consistent	 with	
findings	 in	 other	 network‐based	 studies	 (Cristino	 et	 al.,	 2014a;	 Liu	 et	 al.,	 2014),	 and	
implicates	functional	proximity	as	a	potential	measure	to	identify	other	candidate	ASD	
genes.	For	 instance,	de	novo	LoF	variants	 in	GATAD2B	have	been	observed	 in	patients	
with	limited	speech	(de	Ligt	et	al.,	2012),	and	due	to	its	physical	interaction	with	FOXP2,	
impairment	of	GATAD2B	may	explain	this	 language	development	issue.	Another	study	
proposed	 a	 composite	 gene	 model	 by	 integrating	 brain‐specific	 exon	 expression	 and	
allele	 frequencies	 in	 the	general	population	 (Uddin	et	 al.,	 2014).	This	model	 assumed	
the	 integrity	 of	 gene	 expression	 to	 be	modulated	 by	 selective	 pressure	 on	 particular	
isoform	proteins,	thus	ranking	the	importance	of	genes	that	confer	susceptibility.	In	this	
model,	 genes	 showing	high	 exonic	 expression	 in	 the	brain	 and	 a	 low	allele	 frequency	
significantly	overlapped	with	known	ASD	candidate	genes	relevant	to	fragile‐X	protein	
targets.		
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3.2. Transcriptional convergence and neurodevelopment 
Co‐expression	 networks	 are	 widely	 used	 for	 investigating	 the	 relationship	 between	
genes	 in	 specific	 spatial	 and	 temporal	 contexts.	 These	 networks	 are	 emerging	 as	 a	
powerful	tool	and	incorporate	recent	high‐resolution	transcriptional	profiles	associated	
with	human	brain	development	(Hawrylycz	et	al.,	2012;	Kang	et	al.,	2011;	Miller	et	al.,	
2014).		
The	 most	 common	 approach	 to	 look	 at	 transcriptome	 data	 is	 Weighted‐Gene	 Co‐
expression	 Network	 Analysis	 (WGCNA)	 (Langfelder	 and	 Horvath,	 2008).	WGCNA	 has	
been	used	to	survey	modules	of	highly	correlated	genes	typical	of	specific	brain	regions	
and	developmental	stages.	Voineagu	et	al.	analyzed	postmortem	brains	to	demonstrate	
common	pathophysiological	abnormalities	associated	with	cortical	areas	 in	ASD	cases	
(Voineagu	et	al.,	2011).	They	again	substantiated	numerous	synaptic	and	immune	genes	
were	 found	 to	be	perturbed	 in	 the	 frontal	 and	 temporal	 cortex	of	ASD	cases.	WGCNA	
was	 further	applied	 to	examine	 the	global	differences	 in	 the	organization	of	 the	brain	
transcriptome.	 This	 analysis	 revealed	 salient	 differences	 in	 regional	 gene	 expression	
between	autism	cases	and	controls.	In	the	frontal	and	temporal	cortex,	gene	expression	
patterns	varied	significantly	among	the	controls	but	not	in	ASD	cases,	suggesting	there	
are	 specific	 regional	 abnormalities	 in	 the	 brain.	 Furthermore,	 co‐expression	modules	
similarly	 confirm	 synaptic	 genes	 were	 upregulated,	 whereas	 immune‐related	 genes	
were	downregulated.	The	synaptic	gene	module	was	found	to	be	enriched	with	genome‐
wide	 association	 signals,	 subsequently	 confirmed	 by	 others	 (Ben‐David	 and	 Shifman,	
2012).	Similarly,	 in	a	recent	study	by	Gupta	et	al.	 (2014),	 the	authors	used	WGCNA	to	
identify	 the	 negative	 correlation	 between	 the	module	 of	 activated	M2‐state	microglia	
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genes	and	that	of	synaptic	transmission	genes	from	47	ASD	postmortem	brains	(Gupta	
et	al.,	2014).		
Several	 studies	 have	 now	 combined	 DNA	 variations	 discovered	 from	 genome	
sequencing	with	co‐expression	network	analysis	to	demonstrate	there	is	a	convergence	
of	genetic	variations	in	the	perinatal/postnatal	cerebellar	cortex	and	layer	5/6	cortical	
projection	neurons	(Parikshak	et	al.,	2013;	Willsey	et	al.,	2013).	Parikshak	et	al.	(2013)	
also	demonstrated	ASD	candidate	genes	associated	with	 the	superficial	 cortical	 layers	
during	 early	 neurodevelopment.	 The	 analysis	 of	 co‐expression	 networks	 found	 that	
DNVs	in	ASD	cases	were	enriched	in	the	transcriptional	regulation	module	but	common	
inherited	variants	were	enriched	in	the	synaptic	transmission	module.	Furthermore,	co‐
expression	 modules	 highlighted	 the	 temporal	 and	 spatial	 difference	 contributes	 to	
developmental	 trajectories.	 From	 the	 prenatal	 period	 to	 infancy,	 the	 level	 of	 genes	
involved	in	transcriptional	regulation	decreased,	whereas	the	levels	of	genes	involved	in	
synaptic	transmission	increased.	In	the	adult	cortex,	rare	de	novo	and	common	inherited	
variants	were	clustered	in	superficial	cortical	layers	2–4	and	upper	layer	glutamatergic	
neurons.	 A	 study	 by	Willsey	 et	al.	 (2013)	 demonstrated	 the	 gene	 expression	 changes	
associated	with	de	novo	LoF	variants	in	deep	projection	neurons	of	the	mid‐fetal	frontal	
cortex.	 Furthermore,	 these	 variants	were	 enriched	 at	 the	 inner	 cortical	 plate	 and	 the	
cortical	 glutamatergic	 neurons.	 Similarly,	 Li	 et	 al.	 reported	 cortical	 disconnections	 in	
ASD	cases	 (Li	 et	 al.,	 2014).	Combining	genomic	 and	RNA	sequencing	data,	 they	 found	
rare	nonsynonymous	variants	occur	in	genes	involved	in	oligodendrocyte	development,	
which	is	the	major	cell	type	of	the	corpus	callosum.	Taken	together,	these	observations	
suggest	genetically‐driven	developmental	diaschisis	occurs,	whereby	early	dysfunction	
	 21
may	 disrupt	 the	 maturation	 of	 cortical	 circuits	 in	 the	 brain	 and	 contribute	 to	 ASD	
phenotypes	(Wang	et	al.,	2014).	
The	above	examples	 indicate	 co‐expression	network	analysis	 can	be	 integrated	 into	a	
risk	 prediction	 model	 for	 ASD.	 The	 Detecting	 Association	 With	 Networks	 (DAWN)	
model	 proposed	 by	 Liu	 et	 al.	 (Liu	 et	 al.,	 2014)	 determined	 ‘hot	 spots’	 of	 genetic	
associations	within	a	co‐expression	network.	In	addition	to	the	statistical	assessment	of	
de	 novo	 and	 inherited	 variants	 (He	 et	 al.,	 2013)	 showed	 DAWN	 was	 capable	 of	
prioritizing	 possible	 high‐risk	 genes	 in	 the	 mid‐fetal	 pre‐frontal	 and	 motor‐
somatosensory	 neocortex.	 This	 approach	 was	 able	 to	 provide	 a	 rigorous	 assessment	
and	 identification	 of	 causal	 genes	 that	 includes	 evidence	 from	 targeted	 sequencing.	
Another	feature	of	this	model	was	the	identification	of	sub‐networks	centered	on	FOXP1	
and	 PTEN	 clearly	 demonstrate	 convergence	 of	 ASD‐associated	 genes	 in	 neural	
organization	and	language	development.		
4. Conclusions 
In	 this	 review,	 we	 provide	 an	 overview	 of	 published	 ASD	 studies	 based	 on	 genome	
screening	 and	 systems	 biology.	 Recent	 advances	 using	 pedigree‐based	 genome	
screening	have	enabled	more	rigorous	examination	of	genetic	variations.	WES	and	WGS	
studies	have	 led	 to	 the	discovery	of	 rare	de	novo	 and	 inherited	variants	with	putative	
greater	 penetrance	 than	 predicted	 common	 variants.	 Moreover,	 there	 is	 great	 utility	
with	 these	 approaches	 to	 interpret	 biological	 significance	 of	 genetic	 variations	 1)	
examining	causative	DNA	variations	based	on	an	actual	nucleotide	position	 (Ku	et	 al.,	
2013),	 2)	 estimating	 effect	 of	 DNA	 variations	 on	 gene	 expression	 in	 key	 pathways	
(Deriziotis	 et	 al.,	 2014),	 3)	 utilizing	 information	 of	 minor	 allele	 frequency	 and	
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evolutionary	conservation	to	characterize	rare	variations	associated	with	ASD	(An	et	al.,	
2014).		
It	is	now	clear	that	there	is	no	single	ASD‐causing	gene.	Intensive	research	over	the	last	
five	 years	 has	 confirmed	 there	 is	 an	 extensive	 genetic	 heterogeneity	 associated	 with	
ASD.	 This	 is	 supported	 by	 understanding	 that	 DNA	 variations	 often	 converge	 in	
biological	 pathways	 and	 functional	 processes	 and	 are	 shared	 across	 a	 broad	 range	 of	
neurodevelopmental	 and	 neuropsychiatric	 disorders	 or	 specific	 to	 only	 one	 disorder	
(Sullivan	 and	 Posthuma,	 2015).	 Therefore,	 systems	 biology	 approaches	 will	 be	 a	
valuable	 tool	 to	 dissect	 specific	 differences	 between	 disorders	 (Cristino	 et	 al.,	 2014a;	
Parikshak	et	al.,	2013;	Willsey	et	al.,	2013),	and	identify	functional	distribution	of	causal	
DNA	variants	in	individuals	with	ASD	(An	et	al.,	2014).		
There	 are	 now	 an	 impressive	 range	 of	 technologies	 that	 can	 be	 used	 investigate	
functional	 consequences	 of	 genetic	 variations.	 Induced	 pluripotent	 stem	 cells	 (iPSCs)	
are	currently	being	used	to	characterize	the	effect	of	genetic	variations	in	neuronal	cell	
lineages	 involved	 in	 early	neurodevelopment	 (Griesi‐Oliveira	 et	 al.,	 2014).	Generating	
human	 neurons	 from	 iPSCs	 has	 potential	 utility	 comparing	 healthy	 and	 affected	
individuals	that	will	help	characterize	the	role	of	causal	ASD	genes.	The	use	of	clustered	
regularly	 interspaced	 short	 palindromic	 repeats	 (CRISPR)/Cas9	 gene	 editing	 system	
with	 iPS	 cells	 provides	 a	 tractable	 method	 for	 in	 vitro	 analysis	 of	 DNA	 variations	
whereby	 a	 number	 of	 overlaid	 genetic	 elements	 can	 be	 examined	 additively	 or	 in	 a	
subtractive	 fashion	 to	 assess	 relative	 contribution	 to	 risk	 genes	 to	 ASD	 phenotypes	
(Bernier	et	al.,	2014).	Similarly,	these	gene	editing	technologies	can	be	used	in	vivo	and	
aside	 from	 rodent	 models,	 high	 throughput	 small	 model	 species	 (zebra	 fish,	 fly,	
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honeybee	 and	 worm)	 are	 now	 being	 used	 to	 validate	 the	 biological	 relevance	 of	
conserved	 genes	 and	 human	 genetic	 variations	 (Burne	 et	 al.,	 2011),	 including	 their	
contributions	 to	 complex	 behaviors,	 such	 as	 learning	 and	 memory	 (Cristino	 et	 al.,	
2014b).	
In	conclusion,	systems	biology	approaches	have	facilitated	an	important	paradigm	shift	
from	single	gene	to	pathway	etiology	associated	with	ASD.	Nevertheless,	we	are	mindful	
of	 the	 enormous	 task	 of	 analyzing	non‐coding	 regulatory	 information	with	 respect	 to	
DNA	variations.	Determining	the	functional	impact	of	coding	and	non‐coding	regulatory	
DNA	 variations	 remains	 a	 significant	 hurdle	 for	 developing	 a	 truly	 integrated	 omic	
systems	 approach.	 Resources,	 such	 as	 ENCODE	 (Encode	 Project	 Consortium,	 2012),	
FANTOM	 (Fantom	 Consortium,	 2014),	 and	 mirBase	 (Kozomara	 and	 Griffiths‐Jones,	
2011),	need	to	be	integrated	into	current	analysis	pipelines	to	achieve	a	comprehensive	
predictive	systems	model	for	ASD.	
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Figure	1	
Shown	are	de	novo	variants	(DNVs)	that	cluster	in	functional	pathways	associated	with	
ASD.	The	protein‐protein	interaction	network	plots	illustrate	six	gene	families	(calcium	
channel;	sodium	channel;	potassium	channel;	chromodomain‐helicase‐DNA‐binding	
protein;	catenin;	neurexin‐neuroligin)	where	DNVs	frequently	occur	in	ASD	cases.	An	
integrated	HPRD	and	BioGrid	database	(Cristino	et	al.	2014a)	was	used	to	determine	
sub‐networks	(complex)	of	genes	comprised	of	DNVs	and	their	first‐degree	interacting	
partners.	Gene	set	enrichment	analysis	was	performed	using	the	Gene‐Ontology	
database	and	bar	graphs	show	identified	functional	pathways.	The	y‐axis	in	the	bar	
graph	is	an	enrichment	score,	presented	as	a	log10‐transformed	P‐value.			
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Table	1.	De	novo	variants	identified	through	exome	and	genome	sequencing	
Study	 Method	 Probands	 Siblings
D
N
V
s
	
i
n
	
p
r
o
b
a
n
d
s
	
LoF* Missense** Others***	 Total
D
N
V
s
	
i
n
	
s
i
b
l
i
n
g
s
	
LoF* Missense** Others*** Total
O'Roak	2012	 WES 209	 50 38 154(92) 68 260 3 31(21) 16 50
Sanders	2012 WES 225	 200 15 125(87) 32 172 5 82(54) 38 125
Neale	2012	 WES 175	 0 18 101(NA) 50 169 NA NA NA NA
Iossifov	2012 WES 343	 343 61 209(NA) 92 362 30 203(NA) 81 314
Jiang	2013	 WGS 32	 0 5 28(13) 9 42 NA NA NA NA
An	2014	 WES 48	 0 3 18(11) 8 29 NA NA NA NA
De	Rubeis	2014 WES 3,871	 NA 307 2,186	(828) NA 1,135 NA NA NA NA
Iossifov	2014 WES 2,508	 1,911 383 1,667	(NA) 646 2,696 178 1,140 (NA) 490 1,808
	
*	LoF	variants	are	nonsense	variants,	frameshifts	or	splice‐site‐changing	variants	
**The	numbers	in	brackets	indicate	the	number	of	missense	variants	classified	as	putatively	deleterious	by	functional	prediction	
algorithms	(e.g.,	SIFT,	PolyPhen2).		
***	Including	synonymous	and	non‐frameshift	variants		
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Table	2.	Network	approaches	in	ASD	studies	
Study	 Network	type	 Alias Node	source Interaction	source Highlighted	convergent	pathways
Gilman	2011 PPI	network	 NETBAG	
(NEtwork‐Based	
Analysis	of	Genetic	
associations)	
De	novo	copy‐number	
variations	associated	
with	ASD	
BiGG,	BIND,	BioGRID,	
DIP,	HPRD,	InNetDB,	
IntAct,	MINT,	MIPS	
 Actin	filament	organization	(GO:0007015)	
 Axon	(GO:0030424)	
 Cell	maturation	(GO:0048469)	
 Learning	and/or	memory	(GO:0007611)	
 Synapse	(GO:0045202)	
Sakai	2011	 PPI	network		 NA ASD	syndromic	and	
ASD‐associated	genes	
A	yeast	two‐hybrid	
screen	of	a	human	
complementary	DNA	
library	
 Cytoskeleton	(GO:0005856)	
 Postsynaptic	density	(GO:0014069)	
 Small	GTPase‐mediated	signal	transduction	
(GO:0007264)	
 Metabolic	glutamate	receptor	signaling	
pathway	(GO:0007216)	
Cristino	2014a PPI	network	 AXAS	(Autism,	X‐
linked	intellectual	
disabilities,	
Attention	deficit	
hyperactivity	
disorder,	and	
Schizophrenia	PPI	
network)	
Genes	associated	with	
ASD,	ADHD,	SZ	and	
XLID,	and	their	first‐
degree	interacting	
genes	in	the	whole	
PPI	network	
	
BioGRID,	HPRD  Regulation	of	transcription		(GO:0006355)	
 Synaptic	transmission	(GO:0007268)		
 Signal	transduction	(GO:0007165)	
 Cell‐cell	adhesion	(GO:0007155)	
 Intracellular	signaling	cascade	
(GO:0035556)	
Corominas	2014 PPI	network	 ASIN	(Autism	
Spliceform	
Interaction	
Syndromic	ASD	genes,	
de	novo	and	recurrent	
CNVs,	other	variants	
BioGRID,	DIP,	IntAct,	
MINT,	MIPS,	PDB	
Not	provided
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Network) found	in	cytogenic	
screening,	animal	
studies	or	gene‐
expression	studies	
An	2014		 PPI	network	 NA Rare	inherited	and	de	
novo	variants	
BioGRID,	HPRD  Neuron	migration	(GO:0001764)	
 Neurotrophin	signaling	pathway	
(KEGG:04722)	
 L1CAM	interactions	(REACTOME:22205)	
 Trafficking	of	AMPA	receptors	
(REACTOME:18307)	
Voineague	2011 Co‐expression	
network	
NA Co‐expressed	genes	in	
autism	postmortem	
brains	
Co‐expressed	module  Synaptic	transmission	(GO:0007268)		
 Neuropeptide	hormone	activity	
(GO:0005184)	
 Cell‐cell	adhesion	(GO:0007155)	
 Immune	response	(GO:0006955)	
Parikshak	2013 Co‐expression	
network	
NA Co‐expressed	genes	in	
BrainSpan	
developmental	RNA‐
seq	data	
BioGRID,	InWeb  Nucleic	acid	metabolic	process	
(GO:0090304)	
 Zinc	ion	binding	(GO:0008270)	
 Synaptic	transmission	(GO:0007268)		
 Cation‐transporting	ATPase	activity	
Willsey	2013 Co‐expression	
network	
NA High‐confidence	de	
novo	LoF	variant	
genes	and	their	co‐
expressed	genes	in	
Co‐expressed	module  Cortical	projection	neurons	during	mid‐
fetal	periods		
	
	 52
brain	transcriptomics	
data(Kang	et	al.,	
2011)	
Liu	2014	 Co‐expression	
network	
DAWN	(Detecting	
Association	With	
Networks)		
Risk	genes	defined	by	
Transmission	and	de	
novo	association	
(TADA)	model(He	et	
al.,	2013),	and	their		
co‐expressed	genes	in	
brain	transcriptomics	
data(Kang	et	al.,	
2011)	
BioGRID,	HPRD,	
IntAct,	KEA,	KEGG,	
MINT,	MIPS,	SNAVI		
 Transcriptional	regulation		
 Chromatin	regulation	
 Regulation	of	translation		
 Cell	adhesion/migration	
 Transcriptional	regulation	RNA	
polymerase	II	
 Protein	scaffolding		
 Ligase	activity		
	
Li	2014	 PPI	network	 NA Interacting	genes	in	
BioGRID(Stark	et	al.,	
2006)	
BioGRID  Synaptic	transmission	(GO:0007268)		
Hormozdiari 2014 PPI	network	 MAGI	(Merging	
Affected	Genes	
into	Integrated	
networks)	
De	novo variant	genes	
associated	with	ASD,	
epilepsy,	and	
schizophrenia	
HPRD,	StringDB  Long‐term	potentiation	(KEGG:	04720)	
 Synaptic	transmission	(GO:0007268)		
 Regulation	of	transmission	of	nerve	
impulse	(GO:0051970)		
 Regulation	of	neuronal	synaptic	plasticity	
(GO:0048168)		
 SNARE	interaction	and	vesicular	transport	
pathways	(KEGG:	04130)	
Gupta	2014 Co‐expression	 NA Co‐expressed	genes	in	 Co‐expressed	module  Type	I	Interferon	pathway	(GO:0060337)	
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network	 autism	postmortem	
brains	
 Defense	response	to	virus	(GO:0051607)	
 Cytokine‐mediated	signaling	pathway	
(GO:0019221)		
 GABA‐related	ion	channel	activity	
(GO:0022851)	
*	Interaction	sources	include	databases,	including	BiGG	(Schellenberger	et	al.,	2010),	BIND	(Bader	et	al.,	2003),	BioGRID	(Stark	et	al.,	2006),	DIP	
(Xenarios	et	al.,	2002),	HPRD	(Prasad	et	al.,	2009),	KEA	(Lachmann	and	Ma'ayan,	2009),	KEGG	(Kanehisa	and	Goto,	2000),	InNetDB	(Xia	et	al.,	2006),	
IntAct	(Kerrien	et	al.,	2012),	InWeb	(Rossin	et	al.,	2011),	MINT	(Zanzoni	et	al.,	2002),	MIPS	(Mewes	et	al.,	2002),	PDB	(Berman	et	al.,	2003),	SNAVI	
(Ma'ayan	et	al.,	2009),	StringDB	(Szklarczyk	et	al.,	2011)	
	
	
